[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bariatric-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bariatric-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,75,0,25,[9,52,84,113,148,176,197,223,248,274,302,326,346,371,395,422,451,480,508,531,554,578,598,622,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644753","time-restricted-eating-after-bariatric-surgery-100644753",false,"NCT07672821","Time-Restricted Eating After Bariatric Surgery","Comparison of Time-Restricted Intermittent Fasting Diet in Individuals With and Without Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18-65 years with obesity who have not undergone bariatric surgery\n* Adults aged 18-65 years with obesity who have undergone bariatric surgery and experienced insufficient weight loss (IWL) within 18 months post-surgery, -defined as %EWL \\\u003C50% at 18 months\n* Adults aged 18-65 years with obesity who have undergone bariatric surgery and experienced weight regain (WR), defined as \\>25% increase in %EWL from the lowest recorded weight\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Acute illness, active infection, or comorbid conditions limiting treatment efficacy and safety, including: cancer, type 1 diabetes, renal or hepatic failure, recent stroke or myocardial infarction, nephrolithiasis, drug or alcohol abuse, eating disorders, severe depression or other psychiatric disorders, inflammatory bowel disease (IBD), neoplasia, arrhythmic heart disease, heart failure, respiratory failure, or corticosteroid therapy\n* Professional athletes","ALL","18 Years","65 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to compare the effects of time-restricted eating (TRE, 16\u002F8) in adults with obesity who have and have not undergone bariatric surgery (BS). The study will include adults aged 18-65 years: those with obesity who have not undergone BS, and those who have experienced insufficient weight loss (IWL) or weight regain (WR) following BS. Both groups will follow a 16:8 time-restricted eating protocol for 6 weeks, with an 8-hour eating window recommended between 10:00 AM and 6:00 PM, though participants may adjust to other 16-hour fasting windows. Participants will be evaluated before and after the intervention in terms of anthropometric measurements, biochemical parameters, and dietary habits. The study is being conducted at a private hospital in Bursa, Turkey, and is planned to be completed with a total of 40 participants (20 per group).",[28,29,30,31,32],"Obesity & Overweight","Bariatric Surgery","Weight Regain","Weight Regain Post Bariatric Surgery","Time Restricted Feeding",[34,35,29,36,30,37,38],"Time-Restricted Eating","Intermittent Fasting","Obesity","Anthropometric Measurements","Nutritional Assessment","RECRUITING","2026-06-26",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2025-07-12",{"date":47,"type":22},"2026-07-12",{"name":49,"class":50},"Medipol University","OTHER",2,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100643847","3d-reconstruction-vr-and-machine-learning-in-body-image-in-bariatrics-100643847","NCT07668492","3D Reconstruction, VR and Machine Learning in Body Image in Bariatrics","The Use of 3D Reconstruction, Virtual Reality, and Machine Learning in Addressing Body Image in Bariatric Metabolic Surgery.","Inclusion Criteria:\n\n* Tier 4 bariatric group\n* On waiting list for bariatric metabolic surgery\n* Able to stand unaided for at least 5 minutes\n\nExclusion Criteria:\n\n* Anyone who cannot provide informed consent\n* Anyone who is involved in current research or has recently been involved in any research prior to recruitment.","75 Years",{"count":61,"type":22},80,[25],"Studies have shown that following bariatric metabolic surgery (BMS), patients continue to experience dissatisfaction with their new body image and identity). The reason for this is poorly understood but negative body image perception after surgery is linked to poor psychological and clinical outcomes. Our pilot study looking at the acceptability and feasibility of 3D reconstruction and virtual reality (VR) in addressing body image in BMS found that participants felt better informed about how their body will change following significant weight loss and agreed this novel intervention would be beneficial in helping patients adjust to changes in their body after BMS.\n\nThe investigators propose a randomised control trial comparing group body image counselling and group body image counselling with 3D reconstruction and VR in addressing body image in BMS. The study aims to enrol 80 participants from the Tier 4 bariatric group at St Mary's Hospital and Chelsea \\& Westminster Hospital. After consent, participants will be divided into two groups: the control group will receive traditional group body image counselling, and the intervention group will receive the same counselling supplemented with VR and 3D reconstructed images depicting 15% and 25% total less body weight. Both groups will undergo four sessions over six months.\n\nThe investigators will collect data including body measurements and 3D images of the participant in their underwear using a secure password protected device at baseline and follow participants at 3, 6, 9, 12, 18, 24, and 36 months post-BMS. Patient reported outcomes will be assessed through patient-reported questionnaires.\n\nThis trial seeks to determine if integrating 3D reconstruction and VR technology into body image counselling can provide better support for patients adjusting to body image changes post-BMS, potentially leading to improved psychological and clinical outcomes.",[65,66,67,29],"Obesity (Disorder)","Body Image","Mental Health",[69,70,66,71,72],"3D Reconstruction","Virtual Reality","Machine Learning","Bariatric Metabolic Surgery","NOT_YET_RECRUITING","2026-06-19",{"date":76,"type":43},"2026-06-25",{"date":78,"type":22},"2026-06",{"date":80,"type":22},"2030-03",{"name":82,"class":50},"Imperial College London",1,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":102,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":83},"100589244","identification-of-pre-surgical-phenotypic-indicators-predictive-of-quality-of-life-trajectories-in-obese-patients-following-bariatric-surgery-100589244","NCT06951893","Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery","PHENOBEQOL73","Inclusion Criteria:\n\n* patient \\> 18years old\n* Integrated into the GEROM73 surgical program and starting the intra-hospital program\n\nExclusion Criteria:\n\n* Patients in a state of psychiatric decompensation\n* Patients with cognitive disorders\n* Patients with difficulties understanding the French language, spoken or written\n* Pregnant, parturient, or breastfeeding women",{"count":92,"type":22},165,[25],"This study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. In addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety\u002Fdepression scores, eating behaviors and body mass indices.\n\nThis study will be conducted during the usual care of patients undergoing the GEROM73 program, lasting a total of 30 months.\n\nThe GEROM73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. This program supports patients throughout their bariatric care..\n\nThroughout the GEROM73 program, patients will complete questionnaires on anxiety, depression, eating disorders, Impact of Weight on Quality Of Life.\n\nPatients' weight, body mass index and body schema will also be measured throughout the GEROM program.",[96,97,29,98,99,100,101],"Obesity, Morbid","Obesity and Overweight","Bariatric Surgery Patients","Bariatric Surgery Patient","Bariatric Surgery (Sleeve Gastrectomy )","Bypass, Gastric",[103,89],"GEROM73","2026-06-09",{"date":106,"type":43},"2026-06-10",{"date":108,"type":43},"2025-06-17",{"date":110,"type":22},"2030-09-09",{"name":112,"class":50},"Centre Hospitalier Metropole Savoie",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":83},"100643167","evaluation-of-metabolic-parameters-intestinal-permeability-and-gastrointestinal-symptoms-after-bariatric-surgery-in-body-weight-management-100643167","NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","19 Years","50 Years",{"count":21,"type":22},"OBSERVATIONAL","This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[96,29,127,128,129],"Intestinal Permeability","Gastrointestinal Symptoms","Metabolic Syndrome",[131,132,133,134,135,136,137,138],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters","2026-06-08",{"date":141,"type":43},"2026-06-11",{"date":143,"type":22},"2026-07-01",{"date":145,"type":22},"2027-02-01",{"name":147,"class":50},"Toros University",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":156,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":174,"locationsCount":83},"100643754","eating-behavior-nutritional-status-and-appetite-hormones-after-bariatric-surgery-100643754","NCT07636239","Eating Behavior, Nutritional Status and Appetite Hormones After Bariatric Surgery","Evaluation of Changes in Postoperative Eating Behavior Attitudes, Nutritional Status, and Some Hormonal Parameters Regulating Appetite in Surgical Weight Management","BCKYL-YDB","Inclusion Criteria:\n\n* Having undergone Laparoscopic Sleeve Gastrectomy (LSG) within the last month\n* Aged between 18-50 years\n* Signing the informed consent form\n* Having a Body Mass Index (BMI) of 40 kg\u002Fm2 or between 35-40 kg\u002Fm2 with obesity-related comorbidities\n* No diagnosis of depression\n* No eating behavior disorder\n* No psychiatric disorder\n\nExclusion Criteria:\n\n* Not having undergone Laparoscopic Sleeve Gastrectomy (LSG) or not planning to undergo bariatric surgery\n* Not being in the age range of 18-50 years\n* Not signing the informed consent form\n* Having a Body Mass Index (BMI) greater than 40 kg\u002Fm2 or less than 35 kg\u002Fm2 without obesity-related comorbidities\n* Having a diagnosis of depression\n* Having an eating behavior disorder\n* Having a psychiatric disorder",{"count":21,"type":22},"This study aims to evaluate changes in eating behavior attitudes, nutritional status, and appetite-regulating hormonal parameters in individuals who have undergone Laparoscopic Sleeve Gastrectomy (LSG). The study will be conducted at Bursa Yıldırım Doruk Hospital, Department of General Surgery. A total of 40 volunteer participants who underwent LSG within the last month will be included. Participants will be assessed at baseline (shortly after surgery) and at 6-month follow-up. Assessments will include anthropometric measurements (body weight, height, waist and hip circumference, BMI, waist-to-hip ratio), 3-day dietary intake records analyzed using BeBIS 8.2 software, and the Adult Eating Behavior Scale. Biochemical parameters including fasting blood glucose, total cholesterol, triglycerides, HDL, LDL, VLDL cholesterol, and insulin will be obtained from patient files and analyzed using Advia Chemistry 2400 and Advia XPT devices. Additionally, appetite-regulating hormones (ghrelin, GLP-1, PYY) will be analyzed from residual blood samples using the ELISA method with RelAssay Diagnostics kits by Teknogen Bioengineering Laboratory. All data will be compared between baseline and 6-month follow-up to evaluate the impact of bariatric surgery on nutritional and hormonal outcomes.",[36,29,131,159,160],"Eating Behavior","Nutritional Status",[36,29,131,159,162,163,164,165,166,167,168,169],"Nutritional status","Ghrelin","GLP-1","Peptite YY","Appetite hormones","Body mass index","Weight loss","Dietary intake","2026-06-02",{"date":104,"type":43},{"date":143,"type":22},{"date":145,"type":22},{"name":175,"class":50},"Özlem ÖZPAK AKKUŞ",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":51},"100464287","improvement-in-glycemic-response-after-bariatric-surgery-100464287","NCT05325736","Improvement in Glycemic Response After Bariatric Surgery","Inclusion Criteria:\n\n* candidates of bariatric surgery or cholecystectomy\n* age 18-70\n* male\u002Ffemale\n\nExclusion Criteria:\n\n* previous bariatric surgery\n* type 1 diabetes\n* antibiotic treatment 3 months prior to the study\n* probiotic treatment 3 months prior to the study\n* chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders\n* any pathologic findings during endoscopy\n* participants who will suffer from a post-operation complication",true,"70 Years",{"count":185,"type":22},120,"decipher the role of microbiota in glycemic response change after bariatric surgery",[29],"2026-05-19",{"date":190,"type":43},"2026-05-20",{"date":192,"type":43},"2021-07-01",{"date":194,"type":22},"2029-07-01",{"name":196,"class":50},"Weizmann Institute of Science",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":83},"100533156","recovering-from-bariatric-surgery-the-effects-of-early-initiated-and-supervised-mobilization-100533156","NCT06222151","Recovering From Bariatric Surgery: the Effects of Early Initiated and Supervised Mobilization","Inclusion Criteria:\n\n* The ability to read and understand the Danish language\n\nExclusion Criteria:\n\n* Preoperative dependence of walking aids\n* Vision impairment\n* Previous syncopes or epilepsy\n* Admission to the intensive care unit after surgery\n* Acute complications during hospital admission\n* Patients are excluded at baseline if they have an oxygen saturation below 90% or a systolic blood pressure above 180 mmHg",{"count":204,"type":22},112,[25],"The aim is to investigate the effect of early initiated and supervised mobilization continued after discharge as management of postoperative pain and recovery following obesity surgery, including patient experiences, pain coping, physical functionality and quality of life.",[208,209,29,210,211],"Postoperative Pain, Acute","Postoperative Pain, Chronic","Mobilization","Physical Activity",[213,29,214,211,210],"Pain Coping","Postoperative Pain","2026-05-18",{"date":190,"type":43},{"date":218,"type":43},"2024-04-22",{"date":220,"type":22},"2027-12-26",{"name":222,"class":50},"Esbjerg Hospital - University Hospital of Southern Denmark",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":246,"locationsCount":51},"100636747","effect-of-transcutaneous-electrical-nerve-stimulation-on-podd-in-bariatric-surgery-patients-100636747","NCT07569705","Effect of Transcutaneous Electrical Nerve Stimulation on PODD in Bariatric Surgery Patients","Effect of Transcutaneous Electrical Nerve Stimulation on Postoperative Diaphragmatic Dysfunction in Morbidly Obese Patients Undergoing Bariatric Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Body mass index \\> 40 kg\u002Fm2\n* ASA II\n\nExclusion Criteria:\n\n* Limited diaphragmatic ultrasound views\n* Patient with pulmonary diseases (COPD, bronchial asthma, and interstitial fibrosis)\n* Patient refusal","20 Years","60 Years",{"count":233,"type":22},70,[25],"Researchers aim to evaluate impact of transcutaneous electric nerve stimulator on the incidence of postoperative diaphragmatic dysfunction in patients living with obesity undergoing bariatric surgery",[29,237],"Bariatric Surgery Candidate",[239,240],"Bariatric","Diaphragmatic dysfunction","2026-05-17",{"date":190,"type":43},{"date":241,"type":43},{"date":245,"type":22},"2026-08-30",{"name":247,"class":50},"Cairo University",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":83},"100593837","transition-to-ambulatory-bariatric-surgery-tabs-trial-100593837","NCT07011628","Transition to Ambulatory Bariatric Surgery (TABS) Trial","TABS","Inclusion Criteria:\n\n* BMI ≤ 60 kg\u002Fm2\n* Primary Sleeve gastrectomy or Gastric Bypass,\n* Undergoing bariatric surgery at sponsor site\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Myocardial Infarction\n* Unstable Angina or Heart Failure\n* Prior Stroke\n* Solid organ transplantation\n* Systemic glucocorticoid prior 28 days\n* Severe Obstructive Sleep Apnea\n* Uncontrolled Hypertension (Systolic \\> 150, Diastolic \\> 90)\n* Untreated Hyperthyroidism\n* Chronic Kidney Disease (EGFR \\\u003C 60)\n* Current anticoagulant use,\n* Poorly controlled Type 2 diabetes (Hemoglobin A1c in last 3 months \\> 8.5%)\n* Chronic opioid use\n* Insulin dependence.\n* Need for extended venous thromboembolic event prophylaxis,\n* \\> 1 lifetime bariatric surgery (revisional or conversion bariatric surgery)\n* Patient lives \\> 130 miles from the hospital.\n* Tobacco use in last 12 months\n* Desire to become pregnant or active pregnancy\n* Prisoners\n* Unable or unwilling to follow-up\n* Unable to understand or provide consent","25 Years","55 Years",{"count":258,"type":22},200,[25],"This study will compare same day discharge and at least one night stay in the hospital after bariatric surgery. Patients undergoing bariatric surgery will be randomized (i.e. have an equal chance of either plan) to either group. The study's primary outcome is the frequency patients in the study require a visit to the emergency room within 7 days of their surgery.",[262,29],"Obesity and Obesity-related Medical Conditions",[264,265,266,267],"ambulatory surgery","same day discharge","gastric bypass","sleeve gastrectomy",{"date":188,"type":43},{"date":143,"type":22},{"date":271,"type":22},"2028-05-01",{"name":273,"class":50},"Vanderbilt University Medical Center",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":83},"100635973","the-oat-trail-the-obesity-anti-coagulation-thromboprophylaxis-trial-100635973","NCT07559643","The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.","A Prospective, Randomised Controlled Trial Comparing Weight-based Tinzaparin Versus Weight-based Enoxaparin for Peri-operative Thromboprophylaxis in Patients Undergoing Bariatric Surgery: Evaluation of Anti-Xa Levels and Clinical Outcomes.","The OAT-RCT","Inclusion Criteria:\n\n* Age ≥18 years\n* BMI ≥40 kg\u002Fm², or BMI ≥35 kg\u002Fm² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, dyslipidaemia, or metabolic dysfunction-associated steatotic liver disease (MASLD))\n* Scheduled to undergo laparoscopic bariatric surgery (sleeve gastrectomy or gastric bypass) at St Vincent's University Hospital, Dublin, Ireland\n* Capacity to provide written informed consent\n\nExclusion Criteria:\n\n* Current therapeutic anticoagulation for any indication Known allergy or hypersensitivity to tinzaparin, enoxaparin, heparin, or any heparin-derived product, including documented heparin-induced thrombocytopaenia (HIT) Any other contraindication to LMWH therapy Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) Known haematological disorder or coagulopathy Pregnancy, breastfeeding, or planning pregnancy during the study period Active major bleeding or high bleeding risk at the discretion of the treating clinician Inability to provide written informed consent Participation in another interventional clinical study within 30 days prior to enrolment",{"count":283,"type":22},180,[25],"Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery. Most blood clots occur after patients go home from hospital, within the first 30 days after surgery. To prevent blood clots, all patients having weight loss surgery receive a daily blood-thinning injection for 21 days after their operation.\n\nTwo blood-thinning injections are currently used at St Vincent's University Hospital for this purpose: enoxaparin (Clexane®) and tinzaparin (Innohep®). Both belong to a group of medicines called low molecular weight heparins (LMWHs). Patients with obesity process these medicines differently to the general population, and previous studies from our hospital have shown that fewer than 53% of patients achieve adequate blood-thinning levels with either injection when measured by a blood test called an anti-Xa level.\n\nPatients will be randomly assigned (like a coin toss) to receive either tinzaparin or enoxaparin for 21 days after their surgery. Both injections are already in routine use at this hospital. A single extra blood sample will be taken on the second day after surgery to measure the anti-Xa level, which tells us whether the injection is providing adequate protection against blood clots. This blood sample will be taken at the same time as routine post-operative blood tests so that no additional blood draws are required.\n\nThe study will also look at rates of blood clots and bleeding events within 30 days of surgery, and will ask patients to complete a short questionnaire at their six-week follow-up appointment about their experience with the injection.",[29,287,288,28],"Anti-Xa Activity","VTE (Venous Thromboembolism)",[290,291,36,292,293],"Anti-Xa","Metabolic Bariatric Surgery","VTE","DVT","2026-05-14",{"date":215,"type":43},{"date":297,"type":22},"2026-08-01",{"date":299,"type":22},"2026-12-01",{"name":301,"class":50},"University College Dublin",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":312,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":83},"100634433","phase-3-suzetrigine-enhanced-multimodal-opioid-sparing-therapy-in-cardiac-and-bariatric-surgery-100634433","NCT07539623","Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery","SMOOTH-SURG","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Adults 18-85 years old\n* Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)\n* All genders\n\nExclusion Criteria:\n\nAny individual who meets any of the following criteria will be excluded from participation in this study:\n\n* ASA Class V\n* Urgent or emergent surgery\n* Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)\n* History of substance use disorder or chronic opioid use\n* Reoperation\n* Patient refusal or inability to consent\n* Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and\n* Clarithromycin)\n* Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)","85 Years",{"count":311,"type":22},235,[313],"PHASE3","This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.",[29,316,317],"Cardiac Surgery With Sternotomy","Post-operative Pain","2026-05-11",{"date":294,"type":43},{"date":321,"type":43},"2026-05-01",{"date":323,"type":22},"2026-12-22",{"name":325,"class":50},"Icahn School of Medicine at Mount Sinai",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":83},"100571534","phase-4-2024-tirzepatide-bariatric-surgery-100571534","NCT06721507","2024 Tirzepatide-Bariatric Surgery","Preoperative Tirzepatide for Bariatric Surgery","Inclusion Criteria:\n\n* adults who have been enrolled in the multidisciplinary metabolic and bariatric surgery program at the UK HealthCare Weight Loss Surgery Clinic and are scheduled to receive laparoscopic or robotic sleeve gastrectomy, or gastric bypass surgery\n* BMI greater than or equal to 40 kg\u002Fm2 with one or more obesity-related comorbidities\n* have demonstrated abstinence from any form of nicotine use, confirmed by serum nicotine and metabolite testing\n* enrollment in the ADORE Bariatric Tissue Bank (IRB #69767)\n\nExclusion Criteria:\n\n* any contraindication to the use of tirzepatide (per package insert)\n* Personal or family history of medullary thyroid carcinoma\n* Patients with Multiple Endocrine Neoplasm syndrome type 2\n* Hypersensitivity to tirzepatide\n* History of pancreatitis\n* Type 1 Diabetes\n* patients with active, untreated or symptomatic cholelithiasis or jaundice\n* consistent use of a GLP-1 or GLP-1\u002FGIP receptor agonist, over the past 90 days\n* diagnosed autoimmune disease\n* current use of immunosuppressive agents or use within the past 30 days\n* moderate or severe substance use disorder according to DSM-5 criteria\n* uncontrolled significant psychiatric disorder as assessed by specialized bariatric psychologist\n* female participant who is pregnant, breast-feeding, or intends to become pregnant with in 1 year following surgery\n* a prisoner",{"count":334,"type":22},50,[336],"PHASE4","This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity.\n\nThe major objectives are:\n\n1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery.\n2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflammatory profiles, comorbidity resolution (glycemic control, blood pressure, lipid profile), and 30-day surgical complications. Researchers will compare data from patients taking tirzepatide to data from patients not taking tirzepatide before their planned bariatric surgery to see if tirzepatide reduces inflammation and improves health outcomes after bariatric surgery.\n\nParticipants will:\n\nTake or not take tirzepatide, depending on what study group they are in, once a week for 3 months.\n\nVisit the endocrine clinic once a month for 3 months to be prescribed the drug and for checkups regarding side effects due to the drug.\n\nKeep a diary to document taking the drug and any side effects. Continue with their planned bariatric surgery and post-surgery follow-ups according to their healthcare provider.",[262,29],{"date":294,"type":43},{"date":341,"type":43},"2025-03-27",{"date":343,"type":22},"2026-12-31",{"name":345,"class":50},"Marlene Starr",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":83},"100576125","periodontal-microbiota-of-patients-candidates-for-bariatric-surgery-with-body-mass-index-greater-than-30-100576125","NCT06781229","Periodontal Microbiota of Patients Candidates for Bariatric Surgery With Body Mass Index Greater Than 30","Non-interventional Study Exploring the Composition of the Periodontal Microbiota of Patients With Body Mass Index Greater Than 30 That Are Candidates for Bariatric Surgery","OROBESITE","Inclusion Criteria:\n\n* BMI greater than or equal to 30\n* Be on the list of patients scheduled for bariatric surgery,\n* Be able to receive information about the study and understand the information form in order to take part in the study. This implies mastering the French language,\n\nExclusion Criteria:\n\n* Alcohol consumption \\>30g\u002Fd (men) or 20g\u002Fd (women),\n* Having taken antibiotics, prebiotics or probiotics in the month prior to inclusion (this has an influence on the composition of the patient's microbiota),\n* During pregnancy or breastfeeding,\n* For whom oral surgery is planned (surgery for benign or malignant tumours of the maxillary and mandibular bone bases), or with a history of oral surgery in the month prior to inclusion,\n* At risk of infection (existence of one or more of the following known chronic infectious diseases: HIV, HBV, HCV and mononucleosis) and\u002For chronic renal insufficiency (creatinine clearance \\\u003C 60ml\u002Fmin),\n* Patients with a general pathology that contraindicates the performance of diagnostic procedures such as periodontal probing (patients at high risk of infective endocarditis according to the ANSM).\n* Totally edentulous patients",{"count":355,"type":22},170,"The goal of this observational study is to compare the microbiological composition of the periodontal plaque of obese people undergoing bariatric surgery according to their Body Mass Index. The main question it aims to answer is:\n\nDoes obese patients have different microbiote according to their obesity?\n\nObesity being classified in two groups :\n\n* group \"obesity\" for a BMI between 30 and 35\n* versus \"morbid obesity\" group with a BMIabove 35.\n\nParticipants who are scheduled to undergo bariatric surgery as part of their regular medical care will answer questions about their quality of life, hygiene habits, and saliva and periodontal samples will be taken.",[29,96],[359,360,361,167],"microbiological composition","obese","bypass","2026-05-07",{"date":364,"type":43},"2026-05-08",{"date":366,"type":43},"2025-02-03",{"date":368,"type":22},"2028-02-03",{"name":370,"class":50},"University Hospital, Toulouse",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":51},"100576319","mechanistic-and-clinical-outcomes-of-a-surgical-innovation-aimed-at-minimizing-gerd-associated-with-vsg-innovate-vsg-100576319","NCT06783751","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With Vertical Sleeve Gastrectomy (INNOVATE-VSG)","INNOVATE-VSG","Inclusion Criteria:\n\n1. Male and female subjects aged 18-65 years\n2. Body mass index (BMI) 35-55 kg\u002Fm2\n3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management\n4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.\n5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery\n6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery\n7. Must be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Hiatal hernia \\>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)\n2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator\n3. Severe gastroparesis\n4. Previous bariatric or anti-reflux procedure\n5. Barrett's esophagus\n6. Subjects requiring mesh treatment at time of procedure\n7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator\n8. Subjects with pacemakers, implantable defibrillators, neurostimulators\n9. Portal hypertension or cirrhosis\n10. Chronic pancreatitis\n11. Active cancer treatment\n12. Inability to tolerate general anesthesia\n13. Uncontrollable coagulopathy\n14. Significant and uncontrolled inflammatory bowel disease\n15. Severe and\u002For uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.\n16. Suicidal ideation or unstable\u002Funtreated major depressive disorder within the past year\n17. Alcohol or substance use disorder within the past year.\n18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months\n19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions\n20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.",{"count":380,"type":22},44,[25],"This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.",[36,29,384,385],"Sleeve Gastrectomy","Gastroesophageal Reflux Disease","2026-04-08",{"date":388,"type":43},"2026-04-13",{"date":390,"type":43},"2025-03-21",{"date":392,"type":22},"2027-07-31",{"name":394,"class":50},"University of California, Irvine",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100572805","dexmedetomidine-versus-ketamine-as-adjuvants-in-bariatric-surgery-100572805","NCT06738043","Dexmedetomidine Versus Ketamine as Adjuvants in Bariatric Surgery","Dexmedetomidine Infusion Versus Low Dose Ketamine Infusion as an Adjuvant in Bariatric Surgery: A Randomized Controlled Comparative Study","Inclusion Criteria:\n\n* Patients aged 18-60 years.\n* Both sexes.\n* Body mass index (BMI) \\> 35 kg\u002Fm², scheduled for bariatric surgery.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n\nExclusion Criteria:\n\n* History of hypersensitivity to dexmedetomidine or ketamine.\n* History of substance abuse or chronic opioid use.\n* American Society of Anesthesiologists (ASA) physical status III or IV.\n* Severe hepatic or renal impairment.\n* Cardiopulmonary disorders.\n* Severe diabetes mellitus.\n* Psychiatric disorders, seizures, uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg), or heart block.",{"count":403,"type":22},90,[25],"This randomized controlled trial aims to compare the analgesic efficacy of dexmedetomidine infusion versus low-dose ketamine infusion as adjuvants in bariatric surgery. The study includes 90 patients undergoing bariatric surgery at Menoufia University Hospital, randomized into three groups: dexmedetomidine, ketamine, and control (placebo). Primary outcomes include total morphine consumption intra- and post-operatively. Secondary outcomes include postoperative pain scores, total analgesic consumption, time to first analgesic request, hemodynamic parameters, and patient satisfaction. This study seeks to explore safer, more effective pain management strategies to minimize opioid use in bariatric surgery patients.",[36,214,29],[408,409,410,411,412],"Dexmedetomidine","Ketamine","Opioid-Sparing Analgesia","Randomized Controlled Trial","Pain Management","2026-04-05",{"date":415,"type":43},"2026-04-09",{"date":417,"type":22},"2026-04-20",{"date":419,"type":22},"2027-04-20",{"name":421,"class":50},"Tanta University",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":255,"maxAge":19,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":435,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":450},"100613585","impact-of-a-pro-diversity-gut-microbiota-diet-after-a-bariatric-surgery-on-gut-microbiota-eating-behaviour-and-sensory-function-100613585","NCT07268508","Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function","Randomised Controlled Trial Evaluating the Impact of a Pro-diversity Gut Microbiota Diet on Gut Microbiota, Eating Behaviour and Sensory Function in Patients Who Have Undergone Bariatric Surgery","BariaGut Taste","Inclusion Criteria:\n\n* Between 25 and 65 years old\n* Undergoing either sleeve gastrectomy or Roux-en-Y gastric bypass\n* With grade 3 obesity (BMI≥40 kg\u002Fm²) or with BMI≥35 kg\u002Fm² and at least one comorbidity likely to be improved after surgery, with the exception of type 2 diabetes\n* Signed consent form\n* Living less than an hour and 30 minutes from the hospital\n* Presence of effective and stable contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Presence of a contraindication to bariatric surgery\n* Presence of gastrointestinal pathologies with an inflammatory component, known gastroparesis, total gastrectomy, colectomy, exocrine pancreatic insufficiency, known endocrine pathologies inducing hyperglycaemia (uncontrolled dysthyroidism, acromegaly, hypercorticism, etc.), severe chronic renal insufficiency (\\\u003C 30mL\u002Fmin), or hepatocellular insufficiency\n* Claustrophobic\n* Pregnant or breastfeeding women\n* Taking an obesity treatment 3 months before surgery\n* Taking a corticoids, immunosuppression, anabolizing, or growing hormones, antibody treatments less than 3 months before inclusion\n* Daily taking of laxatives or drugs that can strongly interfere with the composition of the intestinal microbiota. If taken sporadically, the patient can be included at a distance (3 weeks) from the laxatives taken.\n* Specific diets (vegetarian, vegan or without gluten)\n* No French speaker\n* Already included in other study\n* Donated blood in the last two months\n* Without freezer access\n* With allergy or intolerance to food propose in ad libitum buffet",{"count":431,"type":22},60,[25],"Bariatric surgery is the most effective treatment for long-term weight loss and reducing obesity-related health risks. It alters the gastrointestinal tract as well as metabolic and hormonal functions, influencing eating behaviour. However, weight loss outcomes and long-term maintenance vary between patients, likely due to changes in the gut microbiota. Dietary recommendations aimed at improving microbiota diversity could help support sustained weight loss after surgery.\n\nThe BariaGut Taste study aims to compare two dietary approaches following bariatric surgery: nutritional counselling promoting gut microbiota diversity versus standard nutritional counselling. One year after surgery, the study will evaluate differences in microbiota diversity, changes in food preferences and eating behaviours, sensory profiles (taste, smell), levels of digestive and gut hormones fasting, before and after eating, cardiometabolic parameters, mental health, physical activity, and more, to better understand Bariatric surgery is the most effective treatment for long-term weight loss and reducing obesity-related health risks. It alters the gastrointestinal tract as well as metabolic and hormonal functions, influencing eating behaviour. However, weight loss outcomes and long-term maintenance vary between patients, likely due to changes in the gut microbiota. Dietary recommendations aimed at improving microbiota diversity could help support sustained weight loss after surgery.\n\nThe BariaGut Taste study aims to compare two dietary approaches following bariatric surgery: nutritional counselling promoting gut microbiota diversity versus standard nutritional counselling. One year after surgery, the study will evaluate differences in microbiota diversity, changes in food preferences and eating behaviours, sensory profiles (taste, smell), levels of digestive and gut hormones fasting, before and after eating, cardiometabolic parameters, mental health, physical activity, and more, to better understand the mechanisms that may explain variations in response to bariatric surgery.\n\nThe BariaGut Taste study is a prospective, randomized, controlled trial with two parallel groups, involving non-diabetic patients aged 25 to 65 y undergoing either sleeve gastrectomy or Roux-en-Y gastric bypass. The trial will be conducted at the digestive surgery department of Edouard Herriot Hospital, the endocrinology-diabetes-nutrition department of Lyon Sud Hospital Center, and the Human Nutrition Research Center Rhône-Alpes. 60 participants are expected to be recruited, with 30 in each arm.\n\nParticipants will be enrolled before surgery during a routine care visit with the surgeon. They will then undergo a metabolic assessment visit conducted exclusively for research purposes. This visit will allow to collect baseline data on primary outcomes via blood, expired air, and stool samples, anthropometric measurements, indirect calorimetry, a battery of questionnaires (TFEQ-21, DEBQ, PHQ-9, SF36, GSES, PANAS, ESUL, BES, DERS, GAD-7, IPAQ, BAQ, GSRS, sensory alterations, Bristol and Likert scales, and FNS), computerized food preference tests (LFPQ), and a standardized, video-recorded ad libitum buffet.\n\nParticipants will be followed up at 3, 6, and 12 months after surgery through visits combining clinical care and research assessments. The dietary interventions specific to each group will be provided since the 3-month visit. The assessments conducted before surgery will be repeated at 6 and 12 months, also integrating clinical care objectives.\n\nAdditional blood, stool, and adipose tissue samples collected during surgery will be stored to create a biobank.",[65,29],[436,437,438,439,440],"Bariatric surgery","gut microbiota","sensory alteration","food preferences","weight loss maintenance","2026-04-02",{"date":443,"type":43},"2026-04-03",{"date":445,"type":43},"2025-11-05",{"date":447,"type":22},"2029-04-05",{"name":449,"class":50},"Hospices Civils de Lyon",3,{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":83},"100592984","indocyanine-green-fluorescence-angiography-icg-fa-in-revisional-bariatric-surgery-100592984","NCT07000539","Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery","Prospective Single-center Diagnostic Parallel-group Study to Determine the Minimal Dose of Indocyanine Green to Observe Vascular Perfussion in Revisional Bariatric Surgery.","BariGreen","Inclusion Criteria:\n\n* Diagnosis of obesity with a BMI ≥ 30 kg\u002Fm²\n* Scheduled for revisional bariatric surgery\n\nExclusion Criteria:\n\n* Allergy to iodides.\n* Anticoagulation with products containing sodium bisulfite (due to the risk of ICG-FA inactivation).\n* Use of radioactive iodine studies within the past 7 days.\n* Pregnant, breastfeeding, or planning to become pregnant within the next year (due to unknown teratogenic or fertility effects of ICG-FA).\n* History of liver disease or laboratory findings suggestive of moderate to severe hepatic disease: total bilirubin \\>1.5 times the upper limit of normal (ULN), or any elevation of aspartate aminotransferase (AST) above ULN.\n* Participants who withdraw their consent to participate in the study (elimination criterion).",{"count":460,"type":22},108,[25],"This study will compare different doses of a green fluorescent product that is administered during weight loss surgery in order to observe where blood vessels are located. There is uncertainty around the optimal dose of this product for patients with obesity, so this study will aim to study if the dose in the minimal range recommended by international guidelines is sufficient for most patients or if higher doses are needed with increasing body mass index.",[36,29],[465,466,467,468,469,470],"bariatric surgery","indocyanine green","vascular","weight loss surgery","Intraoperative Complications","Postoperative Complications","2026-03-23",{"date":473,"type":43},"2026-03-27",{"date":475,"type":43},"2025-05-06",{"date":343,"type":22},{"name":478,"class":479},"Instituto Mexicano del Seguro Social","OTHER_GOV",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":4},"100628084","digital-follow-up-and-nursing-education-in-bariatric-surgery-patients-100628084","NCT07457034","Digital Follow-Up and Nursing Education in Bariatric Surgery Patients","The Effect of the Use of a PHP-MySQL Database-Based Follow-Up System and Nursing Education on Quality of Life in Patients Undergoing Bariatric Surgery","DigiBarQoL","Inclusion Criteria:\n\n* Adults aged 18-65 years Undergoing bariatric surgery Eligible for physical activity participation according to the International Physical Activity Questionnaire (IPAQ) Able to use the PHP-MySQL based digital follow-up system Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Severe cardiopulmonary disease or any medical condition that contraindicates exercise Uncontrolled hypertension or uncontrolled diabetes Severe musculoskeletal limitations preventing participation in the exercise program Severe psychiatric disorder impairing compliance or follow-up Participation in another interventional study during the study period Refusal or inability to provide informed consent",{"count":489,"type":22},52,[25],"This randomized controlled experimental study aims to evaluate the effect of a PHP-MySQL database-based digital follow-up system combined with structured nursing education on quality of life, body mass index (BMI), and exercise habits in patients undergoing bariatric surgery. Although bariatric surgery is an effective treatment for morbid obesity, long-term success depends largely on adherence to lifestyle modifications, including regular physical activity and sustained behavioral change.\n\nParticipants will be randomly assigned to either an intervention group or a control group. The intervention group will receive structured nursing education along with an 8-week digitally monitored exercise program starting at postoperative month four. The control group will receive standard postoperative care. Outcomes will be assessed using the Moorehead-Ardelt Quality of Life Questionnaire II (MA-II), BMI measurements, and the International Physical Activity Questionnaire (IPAQ). The study aims to provide evidence for integrating digital health technologies and structured nursing interventions into postoperative bariatric care.",[493,29],"Obesity (BMI > 35)",[465,495,496,497,498,499,211,411],"obesity","nursing education","digital health","exercise program","Quality of Life","2026-03-03",{"date":502,"type":43},"2026-03-09",{"date":504,"type":22},"2026-03-07",{"date":343,"type":22},{"name":507,"class":50},"Okan University",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":527,"leadSponsor":529,"locationsCount":83},"100626013","flow-controlled-versus-volume-controlled-ventilation-in-bariatric-surgery-100626013","NCT07430111","Flow-Controlled Versus Volume-Controlled Ventilation in Bariatric Surgery","Comparison of Flow-Controlled and Volume-Controlled Ventilation During Bariatric Surgery: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Body mass index (BMI) ≥ 30 kg\u002Fm²\n* ASA physical status II-III\n\nExclusion Criteria:\n\n* ASA physical status I or IV and above\n* Known or previously diagnosed pulmonary disease\n* Patients with severe preoperative pulmonary function impairment (e.g., FEV₁ \\\u003C 50% predicted, severe restrictive or obstructive pathology)\n* Patients with markedly altered lung anatomy or function due to prior major thoracic surgery\n* Patients who were dependent on supplemental oxygen therapy in the preoperative period\n* Refusal to participate in the study or inability to comply with study procedures",{"count":21,"type":22},[25],"This prospective trial aims to compare the effects of flow-controlled ventilation (FCV) and volume-controlled ventilation (VCV) on intraoperative airway pressures and oxygenation in bariatric surgery under general anesthesia. Obesity is associated with altered respiratory mechanics, reduced functional residual capacity, and increased airway pressures, making the selection of an optimal ventilation strategy particularly important in this patient population.\n\nAdult patients aged 18-65 years with a body mass index ≥30 kg\u002Fm² and American Society of Anesthesiologists (ASA) physical status II-III will be allocated to receive either FCV or VCV as part of routine intraoperative mechanical ventilation. Ventilatory parameters, including peak and plateau airway pressures, pulmonary compliance, will be recorded at predefined intraoperative time points.\n\nThe primary endpoint of the study is the PaO₂ value measured at the 20th minute under an FiO₂ of 0.8-1.0.\n\nBy providing comparative data on respiratory mechanics and oxygenation, this study aims to contribute to the identification of lung-protective ventilation strategies and to optimize intraoperative ventilatory management in bariatric surgery.",[36,29,519],"Mechanical Ventilation",[36,521,522],"Flow-Controlled Ventilation","Volume-Controlled Ventilation","2026-02-24",{"date":525,"type":43},"2026-02-25",{"date":523,"type":43},{"date":528,"type":22},"2027-02-18",{"name":530,"class":479},"Ankara Etlik City Hospital",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":542,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":83},"100615234","effects-of-respiratory-muscle-training-in-post-bariatric-surgery-patients-100615234","NCT07289958","Effects of Respiratory Muscle Training in Post-bariatric Surgery Patients","Effects of Respiratory Muscle Training on Cardiovascular, Respiratory, Metabolic and Physical Exercise Capacity Parameters Related to Obesity in Post-bariatric Surgery Patients","Inclusion Criteria:\n\n* Patients diagnosed with obesity within 1 month of bariatric surgery\n* Both sexes\n* Ages 18 to 60\n\nExclusion Criteria:\n\n* Patients with respiratory conditions that contraindicate physical exercise\n* Patients with diagnosed heart disease\n* Patients with psychiatric conditions\n* Patients with osteoarticular conditions that make physical exercise difficult",{"count":489,"type":22},[25],"Obesity is a health condition caused by excessive accumulation of body fat. This condition is linked to the development of chronic diseases and also places increased stress on the respiratory system, leading to respiratory disorders, exacerbation of preexisting respiratory conditions, and a decline in physical capacity and exercise tolerance.\n\nRespiratory muscle training has been shown to have beneficial effects on respiratory function in these patients, although the effects this strategy has on other metabolic and physiological aspects related to exercise and obesity that are affected remain unclear.",[29],[29,543,544],"Inspiratory muscle training","Therapeutic exercise","2026-02-13",{"date":547,"type":43},"2026-02-18",{"date":549,"type":43},"2026-01-05",{"date":551,"type":22},"2027-06-30",{"name":553,"class":50},"University Ramon Llull",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":182,"sex":17,"minAge":561,"maxAge":183,"enrollmentInfo":562,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":563,"conditions":564,"keywords":567,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":83},"100621301","scalp-hair-metabolomics-in-severe-obesity-100621301","NCT07368842","Scalp Hair Metabolomics in Severe Obesity","Scalp Hair Metabolomics as a Novel Biomarker of Poor Metabolic Health in Individuals With Severe Obesity","Inclusion Criteria:\n\nAll subjects:\n\n1. Age 21-70 years\n2. Ability to provide informed consent\n\nHealthy weight controls:\n\n1. BMI of 18.5-24.9 kg\u002Fm2\n2. No chronic disease\n3. No long-term medications\n\nSevere obesity:\n\n1. BMI of \\> 32.5 kg\u002Fm2\n2. Scheduled to undergo bariatric surgery\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Any factors likely to limit adherence to study protocol\n3. Any history of autoimmune or scarring alopecia (eg. alopecia areata, discoid lupus, lichen planopilaris)","21 Years",{"count":431,"type":22},"The purpose of this research study is to investigate how body weight and weight-loss surgery affect the natural chemicals found in scalp hair over time. We will also find out how common and severe hair thinning\u002Fhair loss and muscle loss are in the first 6 months after bariatric surgery.",[28,565,566,29],"Hair Loss","Metabolomics",[495,568,569,465],"hair loss","metabolomics","2026-02-11",{"date":545,"type":43},{"date":573,"type":43},"2026-02-07",{"date":575,"type":22},"2028-02",{"name":577,"class":50},"Singapore General Hospital",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":239,"eligibilityCriteria":583,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":83},"100622052","effect-of-intraoperative-salbutamol-administration-on-mechanical-power-and-respiratory-mechanics-in-obese-patients-undergoing-laparoscopic-bariatric-surgery-100622052","NCT07378605","Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery","Inclusion Criteria:\n\n* Age: 18-65 years\n\nBMI ≥35 kg\u002Fm² (candidates for obesity surgery)\n\nScheduled for elective laparoscopic bariatric surgery\n\nASA physical status I-III\n\nSigned informed consent\n\nExclusion Criteria:\n\nKnown allergy or contraindication to salbutamol\n\nSevere cardiovascular disease (e.g., recent MI, uncontrolled arrhythmia)\n\nPre-existing severe pulmonary disease (e.g., severe COPD, asthma exacerbation)\n\nPregnancy or lactation\n\nEmergency surgery\n\nUse of β-agonists or bronchodilators within 24 hours prior to surgery\n\nPatients with inability to provide informed consent\n\n\\-",{"count":585,"type":22},66,[25],"The primary objective of this study is to evaluate the effect of intraoperative salbutamol administration on mechanical power in obese patients undergoing laparoscopic bariatric surgery under general anesthesia. Mechanical power will be measured at predefined intraoperative time points (T0, T1, and T2), and changes over time will be compared to determine the impact of salbutamol on the overall energy delivered to the respiratory system during mechanical ventilation.\n\nSecondary objectives include the assessment of intraoperative respiratory mechanics, including peak airway pressure (Ppeak), plateau pressure (Pplat), driving pressure (Pdrive), airway resistance (Raw), and lung compliance, as well as gas exchange parameters (SpO₂, EtCO₂) and hemodynamic variables (mean arterial pressure). Postoperative pulmonary outcomes will be evaluated using the Melbourne Group Scale (MGS), with a score greater than 4 indicating the presence of postoperative pulmonary complications. The study aims to investigate whether improvement in intraoperative mechanical power and respiratory mechanics is associated with a reduction in postoperative pulmonary complications in this high-risk population.",[29],"2026-01-22",{"date":591,"type":43},"2026-01-30",{"date":593,"type":22},"2026-01-01",{"date":595,"type":22},"2026-03-15",{"name":597,"class":50},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":605,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":607,"conditions":608,"keywords":610,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":83},"100615005","gastro-intestinal-digestion-and-physiology-after-bariatric-surgery-100615005","NCT07286968","Gastro-Intestinal Digestion and Physiology After Bariatric Surgery","GIBa","Inclusion Criteria:\n\nParticipants eligible for inclusion in this Investigation have to meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. Age: 18-65 years\n\n   Specific inclusion criteria for the different patient populations:\n\n   Patients with obesity:\n3. Body Mass Index: \\> 30 kg\u002Fm2\n\n   Patients after bariatric surgery:\n4. Surgery: at least one year after Roux-en-Y gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\nParticipants eligible for this Investigation must not meet any of the following criteria:\n\n1. Patient has history of more than one bariatric surgery\n2. Patient has a waist circumference \\> 125.6 cm\n3. Patient had gastrointestinal surgery in the past three months\n4. Patient has a pacemaker, defibrillator, infusion pump, or other portable or implanted electromedical device\n5. Patient had frequent exposure to X-rays in the past year\n6. Patient has swallowing disorders, among others: dysphagia for food or pills, any oropharyngeal or oesophageal stricture, anxiety or functional abnormality\n7. Patient has Crohn's disease or Diverticulitis\n8. Patient has gastrointestinal strictures, fistulas or physiological\u002Fmechanical obstructions\n9. Patient has gastric bezoar\n10. Patient has a history of complex bowel resection or known abdominal adhesions\n11. Patient has short bowel syndrome or ostomy\n12. Patient has currently ongoing infections\n13. Patient is planned to undergo usage of rectal foam\u002Fenema or treatment with adjuvant chemotherapy or radiotherapy\n14. Patient is currently on parenteral diet\n15. Patient is planned to undergo MRI procedure during usage of the wireless capsule\n16. Patient is working in a professional healthcare facility (e.g. hospital, dental office, emergency room), military area (e.g. submarine, near radar installation), or heavy industrial area (e.g. power plants, automotive, mining, refineries) during the duration of the clinical investigation\n17. Patient is pregnant, breastfeeding, actively trying to get pregnant or had recent childbirth in last 6 months\n18. Patient cannot discontinue medication that affects gastrointestinal transit time and\u002For pH for at least 3 days before and during the study (and 4 weeks for weekly\u002Flong-acting GLP-1 analogues such as Saxenda, Ozempic, Wegovy, Mounjaro). This includes opioids (e.g., morphine, codeine), proton pump inhibitors (e.g., omeprazole, esomeprazole, pantoprazole), H2-receptor antagonists (e.g., cimetidine, famotidine), antacids, sucralfate, prokinetics (e.g., domperidone, metoclopramide), antidiarrheal agents (e.g., loperamide), antibiotics, probiotics and prebiotics.\n19. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.",{"count":606,"type":22},51,"The goal of this clinical trial is to characterize gastrointestinal digestion and physiology in patients after bariatric surgery, or people living with obesity. The main question it aims to answer is: what is the status of gastrointestinal digestion and physiology after bariatric surgery? Participants will have two study visits: 1) participants will undergo collection of gastrointestinal samples and 2) participants will ingest an ingestible capsule that measures multiple physiological parameters along the gastrointestinal tract.",[29,609,384,28],"Roux-en Y Gastric Bypass",[611,612],"Gastro-intestinal aspiration","ingestible telemetric capsule","2026-01-15",{"date":615,"type":43},"2026-01-20",{"date":617,"type":22},"2026-01-10",{"date":619,"type":22},"2027-07-01",{"name":621,"class":50},"Universitaire Ziekenhuizen KU Leuven",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":17,"minAge":255,"maxAge":19,"enrollmentInfo":629,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":635,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":83},"100619926","magnetic-compression-anastomosis-procedure-for-partial-jejuno-ileal-diversion-evaluating-the-feasibility-of-a-novel-endoscopic-magnetic-metabolic-interventional-therapy-100619926","NCT07350967","Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel Endoscopic Magnetic Metabolic Interventional Therapy","2025\u002F08\u002FEMMIT","Inclusion Criteria:\n\n1. Participants are willing and able to give informed consent for participation in the study.\n2. Male or Female, aged ≥ 25 years to ≤ 65 years inclusive at the time of informed consent\n3. BMI 30-50\n\n   * Prior sleeve gastrectomy (\\> 12 months) or other metabolic surgical procedures with T2DM (characterized by HbA1c \\> 6.5%) or weight regain\n   * T2DM without a history of gastrectomy or other metabolic surgical procedures (diagnosis for \\> 6M and \\\u003C10 yrs) taking at least oral antidiabetic medication with fasting glucose \\\u003C 200mg\u002Fdl and HbA1c \\>6.5 %\n4. Agrees to abstain from any form of additional bariatric or reconstructive surgery that could influence body weight for a duration of 1 year\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months\n2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)\n3. Current enrolment in another research study or previous participation within 30 days of enrolment\n4. Use of injectable insulin\n5. Uncontrolled T2DM\n6. Uncontrolled hypertension, dyslipidemia, or sleep apnea\n7. Current history of injected Glucagon Like Peptide 1 (GLP1)\n8. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies\n9. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging\n10. Previous intestinal, colonic, or duodenal surgery, excluding bariatric procedures\n11. Prior surgical interventions, trauma, prosthetic implants, diseases, or genetic factors that hinder or contraindicate the procedure, including scarring and abnormal anatomical structures\n12. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum\n13. Refractory gastroesophageal reflux disease (GERD)\n14. Barrett's esophagus\n15. Any anatomical anomaly that obstructs orogastric access via gastroscope and catheters, as well as manipulation techniques\n16. Presence of an implantable pacemaker or defibrillator\n17. Any comorbidity or current physiological condition of the subject that, in the opinion of the surgeon or anesthesiologist, poses safety concerns rendering the subject medically unfit for the procedure. This encompasses any conditions for which endoscopic or laparoscopic surgery would be contraindicated, as well as any significant congenital or acquired anomalies of the gastrointestinal tract at or distal to the magnet placement site\n\nSubjects will be deemed ineligible to participate if they fulfill any of the following criteria:\n\n1\\. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months 2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 3. Current enrolment in another research study or previous participation within 30 days of enrolment 4. Use of injectable insulin 5. Uncontrolled T2DM 6. Uncontrolled hypertension, dyslipidemia, or sleep apnea 7. Current history of injected Glucagon Like Peptide 1 (GLP1) 8. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies 9. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging 10. Previous intestinal, colonic, or duodenal surgery, excluding bariatric procedures 11. Prior surgical interventions, trauma, prosthetic implants, diseases, or genetic factors that hinder or contraindicate the procedure, including scarring and abnormal anatomical structures 12. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum 13. Refractory gastroesophageal reflux disease (GERD) 14. Barrett's esophagus 15. Any anatomical anomaly that obstructs orogastric access via gastroscope and catheters, as well as manipulation techniques 16. Presence of an implantable pacemaker or defibrillator 17. Any comorbidity or current physiological condition of the subject that, in the opinion of the surgeon or anesthesiologist, poses safety concerns rendering the subject medically unfit for the procedure. This encompasses any conditions for which endoscopic or laparoscopic surgery would be contraindicated, as well as any significant congenital or acquired anomalies of the gastrointestinal tract at or distal to the magnet placement site 18. History of small bowel surgery such as small bowel resection 19. Active H. pylori infection (prospective participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.) 20. History of chronic or acute pancreatitis 21. Known active hepatitis or active liver disease 22. Symptomatic gallstones or kidney stones or acute cholecystitis 23. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia 24. Use of anticoagulation therapy (excluding aspirin) which cannot be discontinued for 7 days before and 14 days after the procedure 25. Use of P2Y12 inhibitors (clopidogrel, pasugrel, ticagrelor) which cannot be discontinued for 14 days before and 14 days after the procedure (use of low-dose aspirin allowable) 26. History of serious complications of T2DM including coronary artery disease, hypertension, peripheral vascular disease, diabetic retinopathy, and\u002For diabetes-related soft tissue infection 27. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide) 28. Receiving weight loss medications such as Meridia, Xenical, or over-the-counter weight loss medications 29. Persistent anemia, defined as Hgb\\\u003C10 g dL-1 30. Estimated Glomerular Filtration Rate (eGFR) or Modified of Diet in Renal Disease (MDRD) \\\u003C30 ml\u002Fmin\u002F1.73m2 31. Active systemic infection 32. Chemotherapeutic cancer treatment within past 9 months, history of abdominal radiation, or active malignancy within the past 5 years 33. Active illicit substance abuse or alcoholism 34. Unhealed ulcers, bleeding lesions, tumors, or any other lesions at the target site for magnet deployment 35. Anticipated requirement for MR imaging within the first two months following the procedure 36. Any anatomical anomaly that prevents or contraindicates laparoscopic access and general laparoscopic procedures 37. Underwent a surgical or interventional procedure within 30 days prior to the current procedure 38. Any scheduled surgical or interventional procedure planned within 30 days following the current procedure 39. Any stroke or transient ischemic attack (TIA) within six months prior to obtaining consent 40. Any other serological markers likely to be associated with poor outcomes 41. Inability to adhere to the follow-up schedule and assessments 42. Any circumstance that, according to the investigator's judgment, could hinder the completion of follow-up evaluations up to Day 360 (for instance, a health issue that might elevate the risks linked to study involvement or could obstruct the analysis of study findings, failure to comply with the visit timetable, or inadequate adherence to the treatment protocol)\n\n\\-",{"count":630,"type":22},5,[25],"English, Hindi and Gujarati",[634,29],"Diabetes Type 2",[636],"Magnetic Compression Anastomosis","2026-01-09",{"date":615,"type":43},{"date":640,"type":43},"2025-11-11",{"date":642,"type":22},"2026-11-30",{"name":644,"class":645},"iIDEAS Group Holdings Limited","INDUSTRY",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":654,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":23,"phases":657,"briefSummary":659,"conditions":660,"keywords":665,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":83},"100560330","phase-1-physiologic-response-to-bariatric-surgery-and-the-impact-of-adjunct-semaglutide-in-adolescents-100560330","NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)","PRESSURE","Observation Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Male or female biological sex, age 12 through 24 years\n* In the preoperative pathway for vertical sleeve gastrectomy\n\nExclusion Criteria:\n\n* Planned Roux-en-Y gastric bypass\n* Hypothalamic obesity\n* Type 2 Diabetes\n* Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)\n* Current use of insulin\n\nIntervention\u002FTreatment Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Status post vertical sleeve gastrectomy\n* Male or female biological sex, age 12 through 24 years\n* Meeting minimum nutrition goals\n* Obesity: age 12-17 years: BMI ≥95th%ile for age\u002Fsex \\| age 18-24 years: BMI ≥ 30kg\u002Fm\\^2\n* If entering the Intervention phase from the Observational phase: ≤20% BMI loss at 1 year postop\n* If entering the Intervention phase from the existing patient pool: ≤20% BMI loss at 1-2 years postop\n\nExclusion Criteria:\n\n* Surgically correctable cause of suboptimal postoperative weight loss\n* Known hypersensitivity to any component of semaglutide\n* Personal or family history of medullary thyroid carcinoma\n* Personal history of multiple endocrine neoplasia type 2\n* Hypothalamic Obesity\n* Type 2 Diabetes\n* History of pancreatitis\n* Uncontrolled hypertension\n* Clinically significant arrhythmia or heart disease that could be exacerbated by increased heart rate\n* Malignant neoplasm within the last 5 years\n* Untreated thyroid disorder\n* Tanner Stage 1\n* Baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 5x upper limit of normal\n* Baseline Creatinine \\>1.2mg\u002FdL\n* Active treatment for bulimia nervosa\n* Active major psychiatric disorder limiting informed consent\n* Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Intentional self-harm within the previous 1 month\n* Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation\n* Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (\\\u003C4 weeks prior to enrollment)\n* Use of oral glucocorticoids (within 10 days of baseline visit)\n* Use of metformin (within 3 months of baseline visit)\n* Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)\n* Current use of insulin\n* Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)\n* Current pregnancy\n* For females of reproductive potential: Plan to become pregnant in the next 8 months\n* For females of reproductive potential: Not on contraception (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication","12 Years","24 Years",{"count":21,"type":22},[658],"PHASE1","The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.",[36,661,662,663,29,664],"Adolescent Obesity","Body-Weight Trajectory","Weight Loss Trajectory","Anti-obesity Agents",[36,666,29,667,668,669],"Anti-obesity medication","Bariatric Surgery Post Operative Outcomes","Semaglutide","Sleeve gastrectomy","2026-01-08",{"date":672,"type":43},"2026-01-12",{"date":674,"type":43},"2024-10-11",{"date":676,"type":22},"2027-10-01",{"name":678,"class":50},"University of Colorado, Denver"]